Nicheloom visits: 58,111 all-time · 7,637 in the last 7 days

The opportunity tracker for new startups.

Today: 1,953 launches · Niche of the day: specialized calculation tools · See what launched today →

FinalDose: The first programmable drug to cure all cancers

FinalDose is building the first programmable drug platform - a single smart drug molecule that finds diseased cells by their DNA and destroys them. We’re starting with all cancers.

Get picks like this daily. Today's launch numbers, the top launches, AI and tech news, and a daily opportunity pick, straight to your inbox.

Want to reach these readers? Sponsor an issue.

YC · launched May 12, 2026 · 37 upvotes (top 22%) · 2 views

Niche: computational biology and chemistry software · 119 launches, 7 in the last 7 days ▲ +17% · Explore this niche →

Category and tags

  • Healthcare
  • Hardware & robotics
  • B2B
  • Not AI
  • Commercial product
  • Gene Therapy
  • Therapeutics
  • Genetic Engineering
  • AI

Visit website ↗ Source listing ↗

Could you build this?

No FinalDose is developing programmable molecular biotechnology and cancer therapeutics, which is fundamentally a wet-lab biology and clinical science challenge.

What it would actually take: Developing this requires molecular biology laboratories, CRISPR/oligonucleotide synthesis, targeted DNA-cleavage biochemistry, and extensive in vitro and in vivo pre-clinical trials. It demands teams of oncology researchers, biochemists, and geneticists, backed by tens of millions of dollars in biotech laboratory infrastructure and regulatory approvals.

Competitors

Other products that read as similar to this one : 31 launches clear the similarity bar, closest 8 shown.

Attention rank: #5 of 32 (itself plus its competitors, highest first, normalized so YC and Product Hunt are compared fairly).

Launched 189 days after the earliest competitor.

The niche, labels, vibe code rating and competitor comparison on this page are analysis by Nicheloom. If you use them, please credit nicheloom.com. How you may use our data.